Depression
Conditions
Keywords
depression, chronic renal failures, end stage renal disease
Brief summary
The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.
Detailed description
Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.
Interventions
DRUGFluoxetine
Fluoxetine will be dosed at 90 mg once a week
Sponsors
Creighton University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of chronic renal failure and end stage renal disease * Ongoing need for regular dialysis treatment * Diagnosis of depression based on DSMIV * Age tween 19-65 years
Exclusion criteria
* Inability to provide informed consent * Medically or psychiatrically unstable, as defined by requiring inpatient treatment * Pregnancy, nursing or refusal to use a reliable method of birth control in women * Patients with known allergy to fluoxetine, or previous treatment failure of fluoxetine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the efficacy and tolerability of once-weekly fluoxetine in patients with End Stage Renal Disorder who have been diagnosed with depression | Patients will come in for once weekly visits for 12 weeks |
Countries
United States
Outcome results
None listed